leafman101
Well-known member
BioNTech Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Update | BioNTech
Fourth quarter and full year revenues of €5.5 billion 1 and €19.0 billion 1 , respectively Full year net income of €10.3 billion and fully diluted earnings per share of €39.63 ($46.87 2 ) Expect to authorize a share repurchase program of up to $1.5 billion over the next two years and will propose ainvestors.biontech.de
I'm no antivaxxer but I think I'm done with the OG vaccine as a fella who is not old or at risk. Covid is 100% omicron right now. The more you boost, the more your immune response is imprinted to the wildtype virus. Time to shift products, ideally to a more variant-proof vaccine but if they're gonna make any vaccine available in the next few months it should be catered to the current variant.
